Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder
NCT06655883Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of suvorexant in Insomnia, sponsored by Merck & Co. Primary endpoints: Total Sleep Time at Week 8, Adverse Events up to 10 weeks and 2 more. Started Oct 2025; status: recruiting.
02
Drugs
suvorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT06655883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06655883.